2. Anti-infection
  3. RSV
  4. Motavizumab

Motavizumab  (Synonyms: MEDI-524)

Art. -Nr.: HY-P99209 Reinheit: 99.17%
COA
SDS
Technical Support

Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 677010-34-3

Größe Preis Verfügbarkeit Menge
Kostenlose Probe (100 μg)   Jetzt bewerben  
1 mg Auf Lager
5 mg Auf Lager
10 mg Auf Lager
50 mg   Angebot einholen  
100 mg   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Motavizumab Related Antibodies

Top Publications Citing Use of Products

  • Biologische Aktivität

  • Reinheit & Dokumentation

  • Verweise

  • Kundenbewertung

Beschreibung

Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

RSV-F
In Vitro

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription[2].
Motavizumab inhibits F protein-mediated cell-to-cell fusion[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Motavizumab Related Antibodies
In Vivo

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1]
Dosage: 1.25 mg in 0.1 ml of PBS/per mouse
Administration: Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once
Result: Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5.
Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.
Klinische Studie
Accession

A0A0X8XRK2
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molekulargewicht

145.32 kDa

CAS. Nr.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Motavizumab]
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized Human RSV (A2) Post-fusion glycoprotein F Protein (His Tag) can bind Motavizumab. The EC50 for this effect is 3.866 ng/mL.
Reinheit & Dokumentation

Purity: 99.17%

SDS (251 KB)

COA (232 KB) SDS-PAGE (63 KB) SEC-HPLC (172 KB)

Inhibitory Antibodies User Guide (603 KB)
Verweise
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Motavizumab Related Classifications

  • Molaritätsrechner

  • Verdünnungsrechner

Die Formel zur Berechnung von Molaritäten

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)

Diese Gleichung wird häufig abgekürzt als: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Motavizumab677010-34-3MEDI-524MEDI524MEDI 524RSVRespiratory syncytial virusrespiratory syncytial virus infection in high-risk infantsInhibitorinhibitorinhibit

Ihre kürzlich angesehenen Produkte:

Online-Anfrage

Your information is safe with us. * Required Fields.

Produktname

  

Requested Quantity *

Name des Antragstellers *

 

Anrede

E-Mail-Addresse *

 

Telefonnummer *

Department

 

Name der Organisation *

City

Bundesland

Country or Region *

      

Bemerkungen

Massenanfrage

Inquiry Information

Produktname:
Motavizumab
Art. -Nr.:
HY-P99209
Menge:
MCE Japan Authorized Agent:

Kundenbewertung

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Produktname

  

Lot #

Name des Antragstellers *

 

E-Mail-Addresse *

Telefonnummer

 

Department *

Name der Organisation *

 

Country or Region *

Bemerkungen

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.